Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

January 31, 2018January 31, 2018

Compounds Found to Reverse Chemotherapy Resistance in Ovarian Cancer in Lab Tests

News

A research team at Southern Methodist University (SMU) in Dallas, Texas, has identified three compounds that were able to reverse resistance to chemotherapy in ovarian tumors. In lab experiments based on ... Read more

January 3, 2018

Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer

News

Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, ... Read more

December 8, 2017

FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. A decision ... Read more

December 6, 2017

Cytori Ready to Seek EU Approval of ATI-0918 as Bioequivalent to Caelyx for Ovarian Cancer

News

Cytori Therapeutics reports that their compound ATI-0918 is equivalent to Janssen’s Caelyx (doxorubicin) — a previously approved liposomal formulation of doxorubicin hydrochloride for the treatment of ovarian cancer. The data stems ... Read more

November 6, 2017

Siamab’s Antibody-drug Conjugates for Ovarian Cancer Seen to Succeed in Animal Models

News

Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian cancer ... Read more

October 11, 2017December 8, 2017

Clovis Seeks FDA Approval for Rubraca as Ovarian Cancer Maintenance Therapy

News

Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in Boulder, ... Read more

October 2, 2017

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

News

Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 ... Read more

September 11, 2017September 11, 2017

Rubraca as Maintenance Therapy Seen to Aid Survival Without Disease Progression in Range of Patients

News

Rubraca (rucaparib) maintenance treatment significantly improved survival without further disease progression among ovarian cancer patients taking part in a Phase 3 clinical trial, researchers showed in a presentation at the ongoing European Society ... Read more

June 21, 2017June 21, 2017

Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients

News

Clovis Oncology plans to apply to the U.S. Food and Drug Administration (FDA) for expanded approval of Rubraca (rucaparib) as a second-line and later maintenance treatment for all women with ... Read more

June 12, 2017June 12, 2017

Siamab to Present Preclinical Data for ST1 Antibody Drug Conjugates at 2017 BIO International Convention

News

Siamab Therapeutics will present new preclinical data on the safety and efficacy of its flagship ST1 antibody drug conjugates program in ovarian cancer animal models at the 2017 BIO International ... Read more